ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 9

Reflections and Future Directions in R/R ALL

, , ,

Panelists discuss collaboration strategies for chimeric antigen receptor (CAR) T-cell therapy referral, reflections on advancements in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) throughout 2024, key accomplishments, and future opportunities for progress in 2025.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Introduction to CAR T-Cell Therapies in R/R ALL
    EP. 2: Clinical Trials and Real-World Data on Brexu-Cel
    EP. 3: Obe-Cel and MRD Outcomes: Insights and Comparisons
    EP. 4: Shifting Treatment Paradigms in R/R ALL
    EP. 5: Optimizing Bridging Therapies and Post–CAR T Approaches
    EP. 6: Addressing Toxicities in CAR T-Cell Therapy
    EP. 7: Health Care Resource Utilization and Transition of Care
    EP. 8: Outpatient CAR T Therapy and Expanding Access
    Now Viewing
    EP. 9: Reflections and Future Directions in R/R ALL

    Video content above is prompted by the following:

    1. Dr. O’Dwyer to Dr. Logan: How do you partner or collaborate with your affiliated sites and/or community colleagues to ensure patients are being referred to CAR T-cell therapy?

    Closing

    1. Dr. O’Dwyer: Before we wrap up, I’d like to hear your final thoughts and reflections on the strides we made throughout 2024—including new/exciting data presented at ASH 2024. Let’s consider what opportunities/what we are looking forward to ahead in 2025.
      1. What accomplishments in R/R ALL are you most proud of? Which developments stand out as pivotal in shaping clinical practice?
      2. What are you most excited about in 2025? What areas are primed for significant progress? What do you hope to achieve in the coming year?
    x